Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer

Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer

In epithelial ovarian cancer (EOC), carboplatin/cisplatin-induced chemoresistance is a major hurdle to successful treatment. Aerobic glycolysis is a common characteristic of cancer. However, the role of glycolytic metabolism in chemoresistance and its impact on clinical outcomes in EOC are not clear...

Full description

Bibliographic Details
Main Authors: Chae Young Han, David A. Patten, Se Ik Kim, Jung Jin Lim, David W. Chan, Michelle K. Y. Siu, Youngjin Han, Euridice Carmona, Robin J. Parks, Cheol Lee, Li-Jun Di, Zhen Lu, Karen K. L. Chan, Ja-Lok Ku, Elizabeth A. Macdonald, Barbara C. Vanderhyden, Anne-Marie Mes-Masson, Hextan Y. S. Ngan, Annie N. Y. Cheung, Yong Sang Song, Robert C. Bast, Mary-Ellen Harper, Benjamin K. Tsang
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Cancers
Subjects:
epithelial ovarian cancer
chemoresistance
cancer metabolism
hexokinase II
P-p53 (Ser15)
Online Access:https://www.mdpi.com/2072-6694/13/14/3399

Similar Items

Similar Items